Curaxis Pharmaceutical Corp. today offered an update on its clinical development plans for Memryte, its candidate to treat mild-to-moderate Alzheimer’s disease, noting the economic and medical statistics that drive industry-wide research and development.

According to an article from the Alzheimer’s Association, the aggregate cost of care for Alzheimer’s patients in the United States between 2010 and 2050 is forecasted to top $20 trillion dollars. The article also noted that there is no treatment to cure, prevent or delay the progression of Alzheimer’s disease.

Patrick Smith, CEO of Curaxis, said the company’s recent merger and status as a publicly traded company financially positions the company to move forward with future developments of Memryte. Additionally, Smith said that despite reports of other companies’ previous phase 3 trials, in which beta amyloid either failed, or were terminated, Curaxis has remained firm on its differing role of beta amyloids in Alzheimer’s.

“We have maintained for ten years that beta amyloid is a symptom and not a cause of Alzheimer’s and we believe these numerous failed trials confirm that belief. As a result, the pendulum has swung away from beta amyloid as a target and toward a multi-pronged approach such as that offered by Curaxis. Our lead Alzheimer’s candidate, which we call Memryte, addresses the cascade of events that lead to Alzheimer’s, including tau phosphorylation, inflammation and aberrant cell cycling and, as a byproduct, reduces beta amyloid accumulation,” Smith stated in the press release.

The company said that for years it has been working on its patented multi-pronged approach, and as such, has a substantial collection of pre-clinical and clinical research regarding Alzheimer’s.

As Curaxis gears up for its upcoming clinical trials, it said the company is optimistic of the leading role Memryte could play in Alzheimer’s treatment.

“As we ramp up our efforts to launch a phase 2b trial of Memryte in women later this year, we are immensely excited about the opportunity to produce data as compelling as the data obtained in our earlier phase 2a trial in women suffering from mild-to-moderate Alzheimer’s. Based on that data, we believe Memryte could be the first disease modifying treatment for Alzheimer’s disease,” Smith stated.

For more information visit www.curaxispharma.com